-+ 0.00%
-+ 0.00%
-+ 0.00%

Caribou Biosciences Q1 FY26 net loss narrows to $25.09 million; R&D expenses drop to $20.61 million

PUBT·05/07/2026 20:39:14
Listen to the news
Caribou Biosciences Q1 FY26 net loss narrows to $25.09 million; R&D expenses drop to $20.61 million
  • Caribou Biosciences posted a Q1 net loss of USD 25.09 million, narrowing from USD 39.99 million a year earlier; loss per share improved to USD 0.26 from USD 0.43.
  • Operating loss tightened to USD 26.28 million from USD 42.91 million, while revenue was USD 2.4 million, essentially unchanged year over year.
  • R&D expense fell to USD 20.61 million from USD 35.53 million; G&A costs eased to USD 8.07 million from USD 9.74 million.
  • Cash, cash equivalents, and marketable securities declined to USD 118.63 million at March 31 from USD 142.85 million at Dec. 31, with funding expected to support current plans into 2H 2027.
  • FDA alignment reached on pivotal ANTLER-3 phase 3 trial design for vispa-cel in second-line LBCL; RMAT designation secured for CB-011 in relapsed or refractory multiple myeloma, with longer follow-up updates expected in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.